NCT00106600View on ClinicalTrials.gov

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

March 31, 2007

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Pixantrone IV infusion

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

CTI BioPharma
All Listed Sponsors
lead

CTI BioPharma

INDUSTRY

NCT00106600 - Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | Biotech Hunter | Biotech Hunter